Thyroid and androgen receptor signaling are antagonized by
mu-Crystallin in prostate cancer

J 2021

Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER et. al.

Základní údaje

Originální název

Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer

Autoři

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER (826 Velká Británie a Severní Irsko, domácí), Boris TICHÝ (203 Česká republika, domácí), Jan OPPELT (203 Česká republika, domácí), Šárka POSPÍŠILOVÁ (203 Česká republika, domácí), S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL a L. KENNER

Vydání

International journal of cancer, HOBOKEN, International Union Against Cancer, 2021, 0020-7136

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.316

Kód RIV

RIV/00216224:14740/21:00121917

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1002/ijc.33332

UT WoS

000582971700001

Klíčová slova anglicky

μ ‐ Crystallin; androgen receptor; prostate cancer; PSMA‐ PET; thyroid hormone receptor

Štítky

CF GEN, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 10. 2024 09:28, Ing. Martina Blahová

Anotace

V originále

Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3 '-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein mu-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TR alpha/TR beta) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

90132, velká výzkumná infrastruktura

Název: NCMG II

Citovat

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER, Boris TICHÝ, Jan OPPELT, Šárka POSPÍŠILOVÁ, S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL a L. KENNER. Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer. International journal of cancer. HOBOKEN: International Union Against Cancer, 2021, roč. 148, č. 3, s. 731-747. ISSN 0020-7136. Dostupné z: https://dx.doi.org/10.1002/ijc.33332.

@article{1781883,
   author = {Aksoy, O. and Pencik, J. and Hartenbach, M. and Moazzami, A.A. and Schlederer, M. and Balber, T. and Varady, A. and Philippe, C. and Baltzer, P.A. and Mazumder, B. and Whitchurch, J.B. and Roberts, C.J. and Haitel, A. and Herac, M. and Susani, M. and Mitterhauser, M. and Marculescu, R. and StanglandKremser, J. and Hassler, M.R. and Kramer, G. and Shariat, S.F. and Turner, Suzanne Dawn and Tichý, Boris and Oppelt, Jan and Pospíšilová, Šárka and Hartenbach, S. and Tangermann, S. and Egger, G. and Neubauer, H.A. and Moriggl, R. and Culig, Z. and Greiner, G. and Hoermann, G. and Hacker, M. and Heery, D.M. and Merkel, O. and Kenner, L.},
   article_location = {HOBOKEN},
   article_number = {3},
   doi = {http://dx.doi.org/10.1002/ijc.33332},
   keywords = {μ ‐ Crystallin; androgen receptor; prostate cancer; PSMA‐ PET; thyroid hormone receptor},
   language = {eng},
   issn = {0020-7136},
   journal = {International journal of cancer},
   title = {Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ijc.33332},
   volume = {148},
   year = {2021}
}

TY  - JOUR
ID  - 1781883
AU  - Aksoy, O. - Pencik, J. - Hartenbach, M. - Moazzami, A.A. - Schlederer, M. - Balber, T. - Varady, A. - Philippe, C. - Baltzer, P.A. - Mazumder, B. - Whitchurch, J.B. - Roberts, C.J. - Haitel, A. - Herac, M. - Susani, M. - Mitterhauser, M. - Marculescu, R. - Stangl-Kremser, J. - Hassler, M.R. - Kramer, G. - Shariat, S.F. - Turner, Suzanne Dawn - Tichý, Boris - Oppelt, Jan - Pospíšilová, Šárka - Hartenbach, S. - Tangermann, S. - Egger, G. - Neubauer, H.A. - Moriggl, R. - Culig, Z. - Greiner, G. - Hoermann, G. - Hacker, M. - Heery, D.M. - Merkel, O. - Kenner, L.
PY  - 2021
TI  - Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer
JF  - International journal of cancer
VL  - 148
IS  - 3
SP  - 731-747
EP  - 731-747
PB  - International Union Against Cancer
SN  - 00207136
KW  - μ ‐ Crystallin
KW  - androgen receptor
KW  - prostate cancer
KW  - PSMA‐ PET
KW  - thyroid hormone receptor
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ijc.33332
N2  - Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3 '-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein mu-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TR alpha/TR beta) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.
ER  -

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER, Boris TICHÝ, Jan OPPELT, Šárka POSPÍŠILOVÁ, S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL a L. KENNER. Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer. \textit{International journal of cancer}. HOBOKEN: International Union Against Cancer, 2021, roč.~148, č.~3, s.~731-747. ISSN~0020-7136. Dostupné z: https://dx.doi.org/10.1002/ijc.33332.

Podrobný výpis o publikaci